Portal de Periódicos da CAPES

Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma

2024; Massachusetts Medical Society; Volume: 391; Issue: 15 Linguagem: Inglês

10.1056/nejmoa2405888

1533-4406

Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, Hongli Li, Sarah C. Rutherford, Andrew M. Evens, Kelly Davison, Angela Punnett, Susan K. Parsons, Sairah Ahmed, Carla Casulo, Nancy L. Bartlett, Joseph M. Tuscano, Matthew Mei, Brian T. Hess, Ryan Jacobs, Hayder Saeed, Pallawi Torka, Boyu Hu, Craig H. Moskowitz, Supreet Kaur, Gaurav Goyal, Christopher J. Forlenza, Andrew Doan, Adam J. Lamble, Pankaj Kumar, S. Chowdhury, Brett T. Brinker, Namita Sharma, Avina K. Singh, Kristie A. Blum, Anamarija M. Perry, Alexandra E. Kovach, David C. Hodgson, Louis S. Constine, Lale Kostakoglu Shields, Anca Prica, Hildy Dillon, Richard F. Little, Margaret A. Shipp, Michael Crump, Brad S. Kahl, John P. Leonard, Sonali M. Smith, Joo Y. Song, Kara M. Kelly, Jonathan W. Friedberg,

CAR-T cell therapy research

Incorporating brentuximab vedotin into the treatment of advanced-stage classic Hodgkin's lymphoma improves outcomes in adult and pediatric patients. However, brentuximab vedotin increases the toxic effects of treatment in adults, more than half of pediatric patients who receive the drug undergo consolidative radiation, and relapse remains a challenge. Programmed death 1 blockade is effective in Hodgkin's lymphoma, including in preliminary studies involving previously untreated patients.